

# Contents

<b>Acknowledgements</b> .....	<b>v</b>
<b>Abstract</b> .....	<b>vii</b>
<b>Keywords</b> .....	<b>vii</b>
<b>Résumé</b> .....	<b>ix</b>
<b>Mots-clés</b> .....	<b>ix</b>
<b>List of Figures</b> .....	<b>xv</b>
<b>List of Tables</b> .....	<b>17</b>
<b>List of Equations</b> .....	<b>17</b>
<b>Chapter 1 Introduction</b> .....	<b>19</b>
1.1 Physiological role of $\alpha$ -syn .....	20
1.1.1 Alpha-synuclein and the synapse .....	20
1.1.2 Alpha-synuclein and the mitochondria .....	21
1.2 Pathological role of $\alpha$ -syn .....	22
1.2.1 Alpha-synuclein misfolding, aggregation and propagation .....	23
1.2.2 Loss of function toxicity .....	24
1.2.3 Alpha-synuclein toxicity affects multiple compartments, but mitochondrial toxicity may prevail .....	25
1.3 Aging as the major risk for PD .....	27
1.3.1 Structural changes in the aging and diseased brain .....	27
1.3.2 Cellular alterations in the aging and diseased brain: neuronal pigments .....	29
1.3.3 Molecular changes in the aging and diseased brain: proteostasis .....	30
1.3.4 Changes in mitochondrial activity .....	32
1.4 Dopaminergic neurons of <i>SNpc</i> – colossus with feet made of clay .....	33
1.5 Animal models of aging and Parkinson’s disease .....	34
1.6 AMPK and its role in neurodegeneration .....	36
1.6.1 Mechanism of AMPK activation .....	37
1.6.2 AMPK in the brain .....	39
1.6.3 AMPK and neurodegeneration .....	39
1.7 Natural products as AMPK activators: the example of urolithins .....	41
1.7.1 Pomegranate fruit as a rich source of bioactive compounds .....	42
<b>Chapter 2 Aims of thesis</b> .....	<b>45</b>

<b>Chapter 3</b>	<b>Materials and methods</b> .....	<b>47</b>
3.1	AAV6 viral vectors' production and titration .....	47
3.2	<i>In vitro</i> cultures of E16.5 mouse primary cortical neurons.....	47
3.3	Measurement of neuronal respiration using <i>Seahorse XF96 Analyser</i> .....	47
3.4	Mitochondrial mass estimation using the AAV-encoded mitoDsRed reporter .....	48
3.5	Estimation of the levels of AMPK $\alpha$ 1 and $\alpha$ 2 transcripts using real-time PCR.....	48
3.6	Estimation of the amount of mtDNA using real-time PCR.....	49
3.7	Estimation of the autophagic flux using LC3B-mCherry-EGFP reporter .....	49
3.8	Detection of proteins using Western Blotting .....	50
3.9	Viral vectors' delivery using stereotaxic surgery .....	51
3.10	Application of urolithin A diet in rats .....	51
3.11	Animal behavioral tests .....	52
3.12	Material storage and sample processing using microtome.....	52
3.13	Immunohistochemistry.....	53
3.13.1	Immunofluorescent stainings.....	53
3.13.2	DAB immunostaining.....	53
3.14	Evaluation of striatal TH-positive fibers' loss using optical densitometry.....	54
3.15	Evaluation of $\alpha$ -syn aggregation in <i>STR</i> DA fibers using optical densitometry .....	54
3.16	Stereological evaluation of DA neurons' loss in <i>SNpc</i> .....	54
3.17	Statistical analysis.....	54
<b>Chapter 4</b>	<b>Low but chronic AMPK activity is neuroprotective against <math>\alpha</math>-synuclein toxicity <i>in vivo</i></b> .....	<b>55</b>
4.1	Results .....	56
4.1.1	Co-overexpression of alpha-synuclein and AMPK $\alpha$ results in reduction of the level of AMPK $\alpha$ subunit in neuronal cells .....	56
4.1.2	Overexpression of the AMPK $\alpha$ 2 subunit protects dopaminergic neurons from $\alpha$ -syn toxicity <i>in vivo</i> , in an AMPK complex dependent manner .....	60
4.1.3	Overexpression of the T172D $\alpha$ 1 AMPK variant provides the most effective protection of dopaminergic neurons against the toxic effects of $\alpha$ -syn accumulation .....	62
4.1.4	T172D $\alpha$ 1 AMPK variant decreases accumulation of pathologic $\alpha$ -syn in the <i>striatum</i> .....	65
4.1.5	Accumulation of human $\alpha$ -syn increases autophagic activity in cortical neurons overexpressing AMPK $\alpha$ 67	
4.1.6	AMPK $\alpha$ increases mitochondrial mass in neurons overexpressing human $\alpha$ -syn.....	69
4.1.7	Overexpression of AMPK $\alpha$ changes the mitochondrial activity profile of neurons expressing human $\alpha$ -syn	71
4.2	Discussion .....	73
4.2.1	Alpha-synuclein overexpression does not induce AMPK phosphorylation but reduces total levels of AMPK <i>in vitro</i> .....	74
4.2.2	Overexpression of AMPK is neuroprotective against $\alpha$ -syn in nigral dopaminergic neurons .....	74
4.2.3	Constitutive low AMPK activity is the most neuroprotective approach against $\alpha$ -syn <i>in vivo</i> .....	75
4.2.4	Overexpression of AMPK $\alpha$ alters mitochondrial and lysosomal activities in neurons expressing $\alpha$ -syn76	

4.2.5	Modulating AMPK activity: a neuroprotective approach in PD?	76
<b>Chapter 5</b>	<b>Urolithins, natural compounds in the treatment of <math>\alpha</math>-synuclein pathology</b>	<b>79</b>
5.1	Results	80
5.1.1	Urolithin A shows dose-dependent neuroprotective effects on nigral dopamine neurons overexpressing human $\alpha$ -synuclein	80
5.1.2	Short-term treatment with urolithin B induces AMPK-dependent changes in the mitochondrial respiration profile	83
5.1.3	Neurons treated with urolithins show a progressive increase of the mitochondrial mass	85
5.1.4	Treatment of cortical neurons with urolithin B induces increase in basal oxygen consumption rate with and without $\alpha$ -syn being overexpressed	87
5.2	Discussion	89
5.2.1	Urolithin A treatment is neuroprotective against $\alpha$ -syn <i>in vivo</i>	89
5.2.2	<i>In vitro</i> , treatment with urolithins leads to mitochondrial biogenesis and enhanced respiration, in particular when $\alpha$ -syn is overexpressed	91
<b>Chapter 6</b>	<b>Conclusions and perspectives</b>	<b>93</b>
6.1	Overexpression of AMPK $\alpha$ leads to neuroprotection against $\alpha$ -syn toxicity <i>in vivo</i>	93
6.2	Urolithins as potential nutraceuticals in the treatment of Parkinson's disease	96
<b>Chapter 7</b>	<b>Concluding remarks</b>	<b>99</b>
	<b>References</b>	<b>101</b>
	<b>Abbreviations</b>	<b>117</b>
	<b>Appendix</b>	<b>123</b>
	<b>Curriculum Vitae</b>	<b>125</b>